Name: 글로벌 시장 동향
SKU: PH7205
Availability: InStock

보고서 요약(국문)

개요
전 세계 박리성 어린선 치료 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
박리성 어린선은 콜로디온 아기, 콜로디온 아기 증후군 또는 선천성 박리성 어린선으로도 알려져 있습니다. 이는 출생 시부터 나타나는 드문 유전성 피부 질환으로, 주로 피부 발적과 광범위한 비늘 벗겨짐이 특징입니다. 상염색체 열성 선천성 어린선(ARCI)이라고 불리는 세 가지 유전성 피부 질환 중 하나입니다. 이 피부 질환은 여러 유전자의 유해한 변이로 인해 발생합니다. 이 질환과 관련된 가장 흔한 유전자는 TGM1입니다. 다른 유전자로는 NIPAL4, ALOX12B 및 CYP4F22가 있습니다.
또한, 박리성 어린선은 생명을 위협하는 질환은 아니지만 심각한 피부 변형을 유발하며, 아직 입증된 치료법은 없습니다. 치료의 주된 목표는 주로 증상 완화이며, 과도한 경피 수분 손실과 그로 인한 감염을 막는 것입니다. 일반적으로 바셀린이나 라놀린을 함유한 보습 크림, 연화제, 각질 용해 크림(비늘 제거 크림) 등을 국소적으로 사용하여 치료합니다. 항생제와 레티노이드(합성 비타민 A 유도체)도 치료에 사용됩니다.
시장 동향: 성장 요인
국소 치료제 사용 증가
국소 치료제의 사용 증가와 새롭고 발전된 국소 치료제의 개발은 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 보습 크림 등의 국소 치료제는 두꺼운 비늘과 건조한 피부 등 박리성 어린선의 가시적인 증상을 관리하는 데 중요합니다. 국소적인 증상 완화 효과가 이러한 치료제의 사용 증가에 기여하고 있습니다. 많은 제약 회사들이 새로운 국소 치료제 개발에 집중하고 있습니다.

예를 들어, 희귀 및 난치성 피부 질환 치료제 개발 및 상용화에 주력하는 임상 단계 바이오제약 회사인 Timber Pharmaceuticals, Inc.는 2022년 4월 28일, 자사의 특허받은 IPEG 전달 시스템을 사용하여 제형화된 국소 이소트레티노인 TMB-001에 대해 미국 식품의약국(FDA)으로부터 신속심사(Fast Track) 지정을 받았다고 발표했습니다. TMB-001은 X-염색체 열성 어린선(XRI) 및 상염색체 열성 선천성 어린선인 박리성 어린선 치료제입니다.
더욱이, 박리성 어린선의 유병률이 증가함에 따라 환자 치료 결과 개선을 위한 국소 제제에 대한 수요가 증가하고 있습니다. 예를 들어, 미국 국립보건원(NIH)에 따르면, 희귀 유전성 피부 질환인 박리성 어린선은 모든 인구 집단에 영향을 미치며, 유병률은 30만 명당 1명 미만입니다.

또한, 경구 투여 또는 주사로 투여하는 전신 약물과 달리, 국소 약물은 전신 부작용의 위험을 줄여 보다 국소적인 효과를 나타냅니다. 이러한 장점 덕분에 국소 약물은 박리성 어린선 치료에 장기간 사용하기에 적합합니다. 국소 약물은 사용이 간편하고 환자의 편의성을 높여 치료 순응도를 향상시키는 것으로 알려져 있습니다. 이러한 이유로 박리성 어린선 치료에 국소 약물 사용이 증가하고 있습니다.
더 나아가, 박리성 어린선의 유병률 증가, 임상 시험 증가, 질병에 대한 인식 제고, 맞춤형 치료에 대한 수요 증가, 그리고 신약 및 국소 치료법 개발의 진전은 향후 시장 성장을 견인할 것으로 예상되는 요인입니다.

반면, 국소 크림 및 기타 약물과 관련된 합병증 및 부작용, 높은 치료 비용, 대체 치료법의 존재, 그리고 박리성 어린선 치료에 대한 더 나은 치료법의 부재는 시장 성장을 저해할 것으로 예상됩니다.

이 보고서에 대한 자세한 내용은 샘플을 요청하세요.
세그먼트 분석
전 세계 박리성 어린선 치료 시장은 치료 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
보습 크림 부문은 박리성 어린선 치료 시장 점유율의 약 53.2%를 차지했습니다.
보습 크림 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 일반적으로 박리성 어린선은 완치할 수 없지만, 보습 크림은 증상 관리를 위한 1차 치료제로 간주됩니다. 보습 크림 사용의 주요 목적은 증상 완화입니다. 피부를 적절하게 보습함으로써 이러한 크림은 박리성 어린선과 관련된 가려움증, 각질, 불편함을 줄이는 데 도움이 됩니다.
또한, 박리성 어린선에서 건조하고 비늘처럼 벗겨지는 피부는 갈라짐과 균열로 이어질 수 있습니다. 보습 크림은 피부에 보호막을 형성하여 이러한 균열 형성을 방지하고 감염 위험을 최소화하는 것으로 알려져 있습니다. 보습 크림을 꾸준히 사용하면 피부결이 개선됩니다. 비늘이 덜 두드러지고 피부가 더 매끄러워져 전반적인 외관이 향상될 수 있습니다.
박리성 어린선에 사용되는 많은 보습 크림은 처방전 없이 약국에서 구입할 수 있어 환자들이 쉽게 이용할 수 있습니다. 이러한 접근성 덕분에 보습 크림이 널리 사용되고 있으며, 그 보급 확대는 보습 크림에 대한 수요 증가로 이어집니다.
지역별 분석
북미 지역은 시장 점유율의 약 38.4%를 차지했습니다.
북미 지역은 활발한 연구 활동과 선진 의료 시설 덕분에 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 특히 미국을 중심으로 최첨단 의료 시설, 전문 클리닉, 잘 구축된 의료 시설 등 선진 의료 인프라를 자랑합니다. 이러한 시설들은 박리성 어린선의 치료 및 관리를 지원합니다. 선진 의료 인프라는 첨단 치료법에 대한 접근성을 높여 시장 성장에 기여합니다.

이 지역에서 발병률이 증가함에 따라 시장 수요가 증가할 것으로 예상됩니다. 예를 들어, 미국 국립보건원(NIH)에 따르면 미국에서는 10만 명당 1명꼴로 박리성 어린선이 발병하는 것으로 추정됩니다.
또한 미국에는 수많은 연구 기관, 제약 회사 및 학술 센터가 있습니다. 이 지역의 활발한 연구 활동은 박리성 어린선에 대한 이해를 높이고 환자 예후 개선을 위한 새로운 치료법 개발에 기여합니다. 지속적인 연구는 혁신과 새로운 치료법 발견을 촉진하여 이 지역 시장에 긍정적인 영향을 미칠 수 있습니다.
경쟁 환경
박리성 어린선 치료 시장의 주요 글로벌 기업으로는 LGM Pharma, Mylan Inc., Sebapharma GmbH & Co. KG, Timber Pharmaceuticals LLC, Galderma SA, Beiersdorf AG, DFB Technology, Ltd., Unilever PLC, LANOLIPS PTY LTD 및 Lanolin Beauty International 등이 있습니다.

COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 박리성 어린선 치료 시장에 상당한 영향을 미쳤습니다. 팬데믹 기간 동안 COVID-19 팬데믹 및 관련 제한 조치에 대한 관심이 집중되면서 진행 중이던 임상 시험 및 연구 활동이 일시적으로 중단되었습니다. 많은 연구 기관과 제약 회사는 임상 시험 수행, 참가자 모집, 연구 활동의 지속성 확보에 어려움을 겪었습니다. 이로 인해 박리성 어린선에 대한 새로운 치료법 개발이 지연되었을 수 있습니다. 또한 팬데믹은 전 세계적으로 이러한 치료제의 공급망에 차질을 초래했습니다.
보고서 구매 이유

• 치료 유형, 투여 경로, 유통 채널 및 지역별 전 세계 박리성 어린선 치료 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별하기 위해
• 모든 세그먼트를 포함한 박리성 어린선 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 포함된 PDF 보고서

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 층판어류증 치료 시장 보고서는 약 61개의 표, 61개의 그림, 그리고 187페이지 분량입니다.
2023년 주요 고객층
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global lamellar ichthyosis treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Lamellar ichthyosis is also known as collodion baby, collodion baby syndrome, or congenital lamellar ichthyosis. It is a rare genetic skin disorder that is present at birth, mainly characterized by cutaneous redness and extensive scaling. It is one of three genetic skin disorders called autosomal recessive congenital ichthyoses (ARCI). This skin disorder is caused by harmful changes in several genes. The most common gene related to this condition is TGM1. Other genes include NIPAL4, ALOX12B, and CYP4F22.
Moreover, lamellar ichthyosis is not life-threatening but causes severe skin disfigurement and there is no proven cure. The main goal of treatment, which mostly addresses symptoms, is to stop excessive transepidermal water loss and subsequent infections. It is usually treated topically by using moisturizing creams containing petrolatum or lanolin, emollients, keratolytic (anti-scaling) creams and others. Antibiotics and retinoids (synthetic vitamin A derivative drugs) are also used in treatment.
Market Dynamics: Drivers
Increasing adoption of topical medications
The increasing adoption of topical medicines and the development of novel and advanced topical medications are expected to drive the market over the forecast period. Topical medicines such as moisturizing creams and others are crucial for managing the visible symptoms of lamellar ichthyosis, such as thick scales on the skin and dry skin. Their ability to provide localized relief contributes to their increased adoption. Many pharmaceutical companies are focussing on the development of novel topical agents.
For instance, on April 28, 2022, Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, cleared that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, for the treatment of X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis, lamellar ichthyosis.
Moreover, the increasing prevalence of lamellar ichthyosis is increasing the demand for the topical agents for the better patient outcomes. For instance, according to the National Institute of Health (NIH), lamellar ichthyosis, a rare genetic skin disorder affects all populations, and the prevalence is less than 1 case per 300,000 individuals.
In addition, unlike systemic medications taken orally or by injection, topical medicines have a more localized effect by reducing the risk of systemic side effects. This makes them a preferred choice for long-term use in the treatment of lamellar ichthyosis. Topical medications are known for easier to apply and are more convenient for patients by enhancing treatment adherence. This increases the adoption of topical medications for the treatment of lamellar ichthyosis.
Further, the increasing prevalence of lamellar ichthyosis, increasing clinical trials, increasing awareness, increasing demand for personalized treatment options and advancements in the development of novel drugs and topical therapies are the factors expected to drive the market over the forecast period.
Restraints
Factors such as complications and adverse effects associated with topical creams and other drugs, the high cost of the treatment, the availability of alternative treatment options and lack of better treatment for the treatment of lamellar ichthyosis are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The global lamellar ichthyosis treatment market is segmented based on treatment type, route of administration, distribution channel and region.
The moisturizing creams segment accounted for approximately 53.2% of the lamellar ichthyosis treatment market share
The moisturizing creams segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for lamellar ichthyosis, but moisturizing creams are considered first-line treatment for the management of the symptoms. The primary goal of using moisturizing creams is to provide symptomatic relief. By keeping the skin adequately moisturized, these creams help reduce itching, flaking, and discomfort associated with lamellar ichthyosis.
Moreover, dry and scaly skin in lamellar ichthyosis can lead to cracks and fissures. Moisturizing creams are known to create a protective layer on the skin, preventing these fissures from forming and minimizing the risk of infection. Regular use of moisturizing creams contributes to an improvement in skin texture. The scales may become less prominent, and the skin may feel smoother, enhancing the overall appearance.
Many moisturizing creams used for lamellar ichthyosis are available over the counter, making them easily accessible to patients without the need for a prescription. This accessibility contributes to their widespread use. In addition, their wide adoption also increases the demand for moisturizing creams.
Geographical Analysis
North America accounted for approximately 38.4% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the increasing research activities and advanced healthcare facilities. North America especially in the United States, boasts advanced healthcare infrastructure, including state-of-the-art medical facilities, specialized clinics, and well-established healthcare facilities. These facilities support the treatment and management of lamellar ichthyosis. Advanced healthcare infrastructure enhances accessibility to advanced therapies and contributes to the overall market growth.
The increasing prevalence in the region is expected to increase the demand for the market. For instance, according to the National Institutes of Health, lamellar ichthyosis is estimated to affect 1 in 100,000 individuals in the United States.
Furthermore, the United States is home to numerous research institutions, pharmaceutical companies, and academic centers. The region's robust research activities contribute to advancements in understanding lamellar ichthyosis and developing novel treatment options for better patient outcomes. Ongoing research fosters innovation and the discovery of new therapies, which can positively impact the market in the region.
Competitive Landscape
The major global players in the lamellar ichthyosis treatment market include LGM Pharma, Mylan Inc., Sebapharma GmbH & Co. KG, Timber Pharmaceuticals LLC, Galderma SA, Beiersdorf AG, DFB Technology, Ltd., Unilever PLC, LANOLIPS PTY LTD and Lanolin Beauty International among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global lamellar ichthyosis treatment market. During the pandemic, the ongoing clinical trials and research activities are temporarily disrupted due to the redirected focus on the COVID-19 pandemic and its related restrictions. Many research institutions and pharmaceutical companies faced challenges in conducting trials, enrolling participants, and ensuring the continuity of research activities. This could have delayed the development of new treatments for lamellar ichthyosis. The pandemic also disrupted the supply chain of these treatment medicines globally.
Why Purchase the Report?
• To visualize the global lamellar ichthyosis treatment market segmentation based on treatment type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of lamellar ichthyosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global lamellar ichthyosis treatment market report would provide approximately 61 tables, 61 figures, and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Adoption of Topical Medications
4.1.2. Restraints
4.1.2.1. Adverse Effects Associated with the Creams
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. Volume Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Moisturizing Creams*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Petrolatum Creams
7.2.4. Lanolin Creams
7.3. Emollients
7.4. Keratolytic (Anti-Scaling) Creams
7.5. Antibiotics
7.6. Retinoids (Synthetic Vitamin A Derivatives Drugs)
7.7. Moisturizing Eye Drops
7.8. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Topical*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Oral
8.4. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. LGM Pharma*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Mylan Inc.
12.3. Sebapharma GmbH & Co. KG
12.4. Timber Pharmaceuticals LLC
12.5. Galderma SA
12.6. Beiersdorf AG
12.7. DFB Technology, Ltd.
12.8. Unilever PLC
12.9. LANOLIPS PTY LTD
12.10. Lanolin Beauty International
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

LGM Pharma, 4. Key Developments, Mylan Inc., Sebapharma GmbH & Co. KG, Timber Pharmaceuticals LLC, Galderma SA, Beiersdorf AG, DFB Technology, Ltd., Unilever PLC, LANOLIPS PTY LTD, Lanolin Beauty International

표 목록 (Tables)

List of Tables

Table 1 Global Lamellar Ichthyosis Treatment Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Lamellar Ichthyosis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Lamellar Ichthyosis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Lamellar Ichthyosis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Lamellar Ichthyosis Treatment Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Lamellar Ichthyosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 7 Global Lamellar Ichthyosis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Lamellar Ichthyosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Lamellar Ichthyosis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Lamellar Ichthyosis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Lamellar Ichthyosis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Lamellar Ichthyosis Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Lamellar Ichthyosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 14 North America Lamellar Ichthyosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Lamellar Ichthyosis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Lamellar Ichthyosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Lamellar Ichthyosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 18 South America Lamellar Ichthyosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Lamellar Ichthyosis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Lamellar Ichthyosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Lamellar Ichthyosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 22 Europe Lamellar Ichthyosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Lamellar Ichthyosis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Lamellar Ichthyosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Lamellar Ichthyosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Lamellar Ichthyosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Lamellar Ichthyosis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Lamellar Ichthyosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Lamellar Ichthyosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Lamellar Ichthyosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Lamellar Ichthyosis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 LGM Pharma: Overview

Table 33 LGM Pharma: Product Portfolio

Table 34 LGM Pharma: Key Developments

Table 35 Mylan Inc.: Overview

Table 36 Mylan Inc.: Product Portfolio

Table 37 Mylan Inc.: Key Developments

Table 38 Sebapharma GmbH & Co. KG: Overview

Table 39 Sebapharma GmbH & Co. KG: Product Portfolio

Table 40 Sebapharma GmbH & Co. KG: Key Developments

Table 41 Timber Pharmaceuticals LLC: Overview

Table 42 Timber Pharmaceuticals LLC: Product Portfolio

Table 43 Timber Pharmaceuticals LLC: Key Developments

Table 44 Galderma SA: Overview

Table 45 Galderma SA: Product Portfolio

Table 46 Galderma SA: Key Developments

Table 47 Beiersdorf AG: Overview

Table 48 Beiersdorf AG: Product Portfolio

Table 49 Beiersdorf AG: Key Developments

Table 50 DFB Technology, Ltd.: Overview

Table 51 DFB Technology, Ltd.: Product Portfolio

Table 52 DFB Technology, Ltd.: Key Developments

Table 53 Unilever PLC: Overview

Table 54 Unilever PLC: Product Portfolio

Table 55 Unilever PLC: Key Developments

Table 56 LANOLIPS PTY LTD: Overview

Table 57 LANOLIPS PTY LTD: Product Portfolio

Table 58 LANOLIPS PTY LTD: Key Developments

Table 59 Lanolin Beauty International: Overview

Table 60 Lanolin Beauty International: Product Portfolio

Table 61 Lanolin Beauty International: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Lamellar Ichthyosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 3 Global Lamellar Ichthyosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Lamellar Ichthyosis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Lamellar Ichthyosis Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Lamellar Ichthyosis Treatment Market Y-o-Y Growth, By Treatment Type, 2022-2030 (%)

Figure 7 Moisturizing Creams Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Emollients Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Keratolytic (Anti-Scaling) Creams Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Antibiotics Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Retinoids (Synthetic Vitamin A Derivatives Drugs) Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Moisturizing Eye Drops Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Others Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Global Lamellar Ichthyosis Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 15 Topical Route of Administration in Global Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Oral Route of Administration in Global Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Others Route of Administration in Global Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Global Lamellar Ichthyosis Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 19 Hospital Pharmacies Distribution Channel in Global Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Retail Pharmacies Distribution Channel in Global Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 Online Pharmacies Distribution Channel in Global Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Global Lamellar Ichthyosis Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 23 North America Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 Asia-Pacific Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Europe Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 South America Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 Middle East and Africa Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 28 North America Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 North America Lamellar Ichthyosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 30 North America Lamellar Ichthyosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 31 North America Lamellar Ichthyosis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 32 North America Lamellar Ichthyosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 33 South America Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 34 South America Lamellar Ichthyosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 35 South America Lamellar Ichthyosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 36 South America Lamellar Ichthyosis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 37 South America Lamellar Ichthyosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 38 Europe Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 39 Europe Lamellar Ichthyosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 40 Europe Lamellar Ichthyosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 41 Europe Lamellar Ichthyosis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 42 Europe Lamellar Ichthyosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 43 Asia-Pacific Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 44 Asia-Pacific Lamellar Ichthyosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 45 Asia-Pacific Lamellar Ichthyosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 46 Asia-Pacific Lamellar Ichthyosis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 47 Asia-Pacific Lamellar Ichthyosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 48 Middle East & Africa Lamellar Ichthyosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 49 Middle East & Africa Lamellar Ichthyosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 50 Middle East & Africa Lamellar Ichthyosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 51 Middle East & Africa Lamellar Ichthyosis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 52 LGM Pharma: Financials

Figure 53 Mylan Inc.: Financials

Figure 54 Sebapharma GmbH & Co. KG: Financials

Figure 55 Timber Pharmaceuticals LLC: Financials

Figure 56 Galderma SA: Financials

Figure 57 Beiersdorf AG: Financials

Figure 58 DFB Technology, Ltd.: Financials

Figure 59 Unilever PLC: Financials

Figure 60 LANOLIPS PTY LTD: Financials

Figure 61 Lanolin Beauty International: Financials

세계 층판어류증 치료 시장 – 2023-2030

Global Lamellar Ichthyosis Treatment Market -2023-2030